Format

Send to

Choose Destination
Breast Cancer Res. 2000;2(3):176-83. Epub 2000 Mar 25.

Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases.

Author information

1
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520-8023, USA. Stern@biomed.med.yale.edu

Abstract

ERBB family receptor tyrosine kinases are overexpressed in a significant subset of breast cancers. One of these receptors, HER2/neu, or ErbB-2, is the target for a new rational therapeutic antibody, Herceptin. Other inhibitors that target this receptor, and another family member, the epidermal growth factor (EGF) receptor, are moving into clinical trials. Both of these receptors are sometimes overexpressed in breast cancer, and still subject to regulation by hormones and other physiological regulators. Optimal use of therapeutics targeting these receptors will require consideration of the several modes of regulation of these receptors and their interactions with steroid receptors.

PMID:
11250707
PMCID:
PMC138772
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center